All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
26 results for "Cancer" and "Prostate and Urologic Cancers"
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide in mCRPC
Protocol No
MERCK-MK-3475-641
Sub Category
Prostate and Urologic Cancers
An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Protocol No
GENENTECH-MYPATHWAY
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Molecular Analysis for Therapy Choice (MATCH)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Protocol No
ECOG-EAY131-MATCH
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Eye/Orbital Cancers
Endocrine Cancers
Breast Cancers
Brain and Spine Cancers
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Protocol No
AZ-D081SC00001-PROPEL
Sub Category
Prostate and Urologic Cancers
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer
Protocol No
NRG-GU006
Sub Category
Prostate and Urologic Cancers
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
The purpose of this study is to evaluate any good and bad effects of treating urothelial of cancer
with atezolizumab plus bevacizumab.
with atezolizumab plus bevacizumab.
Protocol No
HCRN-GU15-215
Sub Category
Prostate and Urologic Cancers
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant) & Durvalumab (Adjuvant) for MIBC (NIAGARA)
Protocol No
AZ-D933RC00001-NIAGARA
Sub Category
Prostate and Urologic Cancers
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Standard Systemic Therapy +/- Definitive Treatment in Treating Metastatic Prostate Cancer
Protocol No
SWOG-S1802
Sub Category
Prostate and Urologic Cancers
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Protocol No
BI-1381-REFMAL485
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Protocol No
RPCI-I-191711
Sub Category
Prostate and Urologic Cancers
Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
The CHAARTED2 Trial HSPC Previously Treated With Docetaxel & ADT
Protocol No
ECOG-EA8153-CHAARTED2
Sub Category
Prostate and Urologic Cancers
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
Protocol No
NRG-GU005
Sub Category
Prostate and Urologic Cancers
Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Protocol No
SWOG-S1316
Sub Category
Gastrointestinal Cancers
Prostate and Urologic Cancers
Gynecologic Cancers